ArticleAsian biomedicine : research, reviews and news2025
The shifting burden of gastrointestinal and liver diseases across 11 Southeast Asian nations: a 1990-2021 systematic analysis from the global burden of disease study.
Article in Asian biomedicine : research, reviews and news, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The shifting burden of gastrointestinal and liver diseases in Southeast Asia and effective control strategies.Asian biomedicine : research, reviews and news · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The burden of gastrointestinal (GI) and liver diseases in Southeast Asian (SEA) nations is substantial and evolving. Understanding contemporary trends is crucial for targeted public health interventions in this heterogeneous region. Objective: To analyze disability-adjusted life years (DALYs) for major GI and liver diseases across 11 SEA nations from 1990 to 2021. Methods: Age-standardized DALY rates per 100,000 were extracted from the Global Burden of Disease (GBD) 2021 study. We analyzed overall trends, causes with the highest relative DALY rate increases per country (1990-2021), and countries with the highest DALY rates per cause (2021). Results: Although infectious GI DALYs such as diarrheal diseases declined, non-communicable disease, particularly GI cancers and chronic liver diseases, showed increasing prominence. Pancreatic cancer DALYs exhibited major relative increases in Indonesia (+61.7%) and Vietnam (+51.6%). Non-alcoholic fatty liver disease (NAFLD)-related DALYs (including cirrhosis) surged in Malaysia (+65.3%) and Thailand (+59.7%). In 2021, Cambodia, Myanmar, and Indonesia faced the highest DALY burdens from chronic hepatitis B and C. Brunei Darussalam, Malaysia, and Thailand led in colorectal cancer DALYs, while Brunei Darussalam also had high pancreatic cancer rates. Conclusion: SEA nations confront a complex and evolving burden of transitioning GI and liver diseases. The persistent high impact of viral hepatitis, coupled with the alarming rise of NAFLD and GI cancers such as pancreatic cancer, underscores the urgent need for tailored national strategies focused on prevention, early detection, and enhanced treatment access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.